Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Waters Corporation    WAT

News SummaryMost relevantAll newsSector newsTweets 

WATERS CRP : Waters Introduces Highest Performing UPLC Ever Engineered – the new ACQUITY UPLC I-Class

share with twitter share with LinkedIn share with facebook
share via e-mail
06/02/2011 | 12:30pm CET
Waters Introduces Highest Performing UPLC Ever Engineered – the new ACQUITY UPLC I-Class
The New ACQUITY UPLC I-Class System Takes Separations Technology to the Next Level by Maximizing Peak Capacity and Extending the Performance of any MS Detector
Milford, Mass. - 2011-06-01

Waters Corporation (WAT:NYSE) today introduced the new Waters® ACQUITY UPLC® I-Class System, the highest performing UPLC® system ever engineered taking UltraPerformance LC® separations technology to the next level.  For scientists challenged by the most difficult separations, the ACQUITY UPLC I-Class features the lowest system dispersion and lowest carryover in the industry today. Low dispersion maximizes peak capacity thereby advancing chromatographic separations and optimizing the performance of any mass spectrometer.

“The scientific discoveries with the biggest potential to improve our lives often rely on samples and compounds that are the most difficult to understand. The ACQUITY UPLC I-Class System was designed specifically for the rapid pace of laboratories on the cutting edge of research,” said Art Caputo, President of the Waters Division. “Design and function of the I-Class are based on continuous customer input resulting in improvements in sub-two-micron separation that only the originator of the technology can exploit. Whether customers need to rapidly analyze sample-limited compounds amid a complex matrix or they seek to optimize the performance of any mass spectrometer on the market, ACQUITY UPLC I-Class enables scientists to solve their most complex separations and detection challenges.”

Keeping pace with today’s most advanced laboratories, the ACQUITY UPLC I-Class System excels when analyzing complex, sample-limited compounds.   Sample-limited compounds include high potency medications, trace levels of food or water contamination, and (advanced) sophisticated biotherapeutics.  These samples can represent complex separation challenges requiring an LC system that can maximize the benefits of sub-two-micron for faster throughput and optimized MS performance.

While there are many innovations built into the new ACQUITY UPLC I-Class, minimal system volume is a new key feature. Reduced system volume significantly decreases dispersion rates for reproducibly higher resolution and superior peak capacity. Reduced dispersion and small peak volumes extend the sensitivity of any mass spectrometer. Additionally, low dispersion footprint allows users to reduce their separation cycle times without impact to the separation as resolution is maintained even for ballistic gradients lasting less than one minute. Also importantly, new   design and materials dramatically reduce sample carryover effects, thus increasing user confidence in results.

The ACQUITY UPLC I-Class also features class leading flexibility and precise sampling capabilities. Depending on application needs, users can choose either the highest precision and lowest dispersion fixed-loop Sample Manager, or the world’s first low dispersion variable volume Sample Manager with a flow-through needle design, which delivers high-precision injections, excellent sample recovery, and lowest sample carryover optimizing the performance for even the most sensitive mass detectors.


Seven years ago, Waters pioneered a new category of chromatographic performance with the commercialization of sub-2-

share with twitter share with LinkedIn share with facebook
share via e-mail
01/13 WATERS CORPORATION : Q4 2016 Financial Results Webcast Invitation
01/06 WATERS : Findings on Chromatography Reported by Investigators at Waters Corporat..
01/04 WATERS : CE-Marks In Vitro Diagnostic MassTrak Vitamin D Solution
01/03 WATERS CORPORATION : Presentation at the 35th Annual J.P. Morgan Healthcare Conf..
2016 WATERS CORPORATION : Presentation at the Goldman Sachs Healthcare CEOs Unscripte..
2016 WATERS : New Preparative SFC Columns Designed to Aid Purification Scale-Up Metho..
2016 WATERS : Researchers from Waters Corporation Describe Findings in Chromatography..
2016 WATERS CORP /DE/ : Change in Directors or Principal Officers, Financial Statemen..
2016 WATERS CORPORATION (NASDAQ : WAT) Files An 8-K Departure of Directors or Certain..
2016 WATERS CORP /DE/ : Change in Directors or Principal Officers, Financial Statemen..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
01/08DJCorrection to Parkinson's Therapy Story
01/08DJParkinson's Therapy Gets Fresh Look From Device Makers
01/08DJParkinson's Therapy Gets Fresh Look From Device Makers
01/08DJParkinson's Therapy Gets Fresh Look From Device Makers
2016 EXCLUSIVE : U.S. regulator poised to approve Abbott purchase of St Jude - source..
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
01/10 Waters Corporation (WAT) presents at 35th Annual J.P. Morgan Healthcare Confe..
2016 Waters Corporation names Sherry Buck as CFO
2016 Tracking Ruane, Cunniff & Goldfarb's Portfolio - Q3 2016 Update
2016 Waters (WAT) Q3 2016 Results - Earnings Call Transcript
2016 Waters Corporation off 12% following Q3 report
Financials ($)
Sales 2016 2 157 M
EBIT 2016 642 M
Net income 2016 516 M
Finance 2016 441 M
Yield 2016 -
P/E ratio 2016 22,25
P/E ratio 2017 20,33
EV / Sales 2016 5,07x
EV / Sales 2017 4,74x
Capitalization 11 387 M
More Financials
Duration : Period :
Waters Corporation Technical Analysis Chart | WAT | US9418481035 | 4-Traders
Full-screen chart
Technical analysis trends WATERS CORPORATION
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 155 $
Spread / Average Target 9,6%
Consensus details
EPS Revisions
More Estimates Revisions
Christopher James O'Connell President, Chief Executive Officer & Director
Douglas A. Berthiaume Chairman
David A. Terricciano Senior Vice President-Global Operations
Sherry L. Buck Chief Financial Officer & Senior Vice President
Edward W. Conard Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PHILIPS-1.83%28 566
More Results